3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Sarcoma, Kaposi
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Epstein-Barr Virus Infections
1
Acquired Immunodeficiency Syndrome
1
Interventions
Rituximab
47
Cyclophosphamide
45
fludarabine
22
Filgrastim
21
Lenalidomide
18
fludarabine phosphate
17
Prednisone
16
Radiotherapy
15
Peripheral Blood Stem Cell Transplantation
15
Etoposide
15
Vincristine
14
Doxorubicin
14
Melphalan
13
Busulfan
13
pembrolizumab
11
Tacrolimus
11
Methotrexate
10
Gemcitabine
10
ibrutinib
9
Bendamustine Hydrochloride
9
Alemtuzumab
9
obinutuzumab
8
Bortezomib
8
Vorinostat
7
Mycophenolic Acid
7
Granulocyte Colony-Stimulating Factor
7
Carboplatin
7
Azacitidine
7
venetoclax
6
Whole-Body Irradiation
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma
×
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn